Arcturus Therapeutics Holdings

ARCT65

$17.05arrow_drop_down0.06%-$0.01

ARCT65

$17.05

arrow_drop_down0.06%-$0.01

Performance History

Key Stats
Open	$17.94
Prev. Close	$18.06
EPS	-2.33
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	15.96	18.26
52 Week Range	14.97	45.00

Ratios







EPS	-2.33

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Arcturus Therapeutics Holdings (ARCT)

Arcturus Therapeutics Holdings Inc (ARCT) is a biopharmaceutical company focused on developing RNA medicines for various diseases. The company's proprietary Messenger RNA (mRNA) therapeutics platform enables the design, development, and production of mRNA medicines that can potentially treat a wide range of diseases, including rare genetic disorders, infectious diseases, and cancer. Arcturus Therapeutics' goal is to transform the way diseases are treated by harnessing the power of mRNA, a molecule that carries the instructions for protein production in the body.

The history of Arcturus Therapeutics Holdings Inc dates back to its founding in 2013. Since then, the company has been dedicated to advancing its mRNA technology platform and developing a robust pipeline of therapeutic candidates. Arcturus Therapeutics has made significant progress in the field of RNA medicine, with multiple clinical-stage programs and strategic partnerships with leading pharmaceutical companies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Joseph E. Payne M.Sc.
Headquarters: San Diego
Employees: 170
Exchange: NASDAQ

add Arcturus Therapeutics Holdings to watchlist

Keep an eye on Arcturus Therapeutics Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Arcturus Therapeutics Holdings 's (ARCT) price per share?

The current price per share for Arcturus Therapeutics Holdings (ARCT) is $17.06. The stock has seen a price change of -$0.01 recently, indicating a -0.06% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Arcturus Therapeutics Holdings (ARCT)?

For Arcturus Therapeutics Holdings (ARCT), the 52-week high is $45, which is 163.79% from the current price. The 52-week low is $14.97, the current price is 13.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Arcturus Therapeutics Holdings (ARCT) a growth stock?

Arcturus Therapeutics Holdings (ARCT) has shown an average price growth of -7.23% over the past three years. It has received a score of 27 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Arcturus Therapeutics Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Arcturus Therapeutics Holdings (ARCT) stock price performance year to date (YTD)?

As of the latest data, Arcturus Therapeutics Holdings (ARCT) has a year-to-date price change of -48.45%. Over the past month, the stock has experienced a price change of -18.3%. Over the last three months, the change has been -22.03%. Over the past six months, the figure is -42.85%. Looking at a longer horizon, the five-year price change stands at 77.51%.

help

Is Arcturus Therapeutics Holdings (ARCT) a profitable company?

Arcturus Therapeutics Holdings (ARCT) has a net income of -$29.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -25.77% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $157.75M, although specific revenue growth data is currently not available. The gross profit is $154.79M. Operating income is noted at -$78.2M. Furthermore, the EBITDA is -$77.01M.

help

What is the market capitalization of Arcturus Therapeutics Holdings (ARCT)?

Arcturus Therapeutics Holdings (ARCT) has a market capitalization of $462.38M. The average daily trading volume is 0, indicating the stock's liquidity and investor engagement.

News

MRNA

CANCER VACCINES

THERAPEUTICS

PERSONALIZED MEDICINE

MULTIVALENT VACCINES

Oct 14, 2024

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

ARCTURUS THERAPEUTICS

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

COVID-19

VACCINE

MRNA

ARCTURUS THERAPEUTICS

CSL

MEIJI SEIKA PHARMA

Sep 13, 2024

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

ARCTURUS THERAPEUTICS

PRICE TARGET

EARNINGS ESTIMATE REVISIONS

Sep 3, 2024

Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

ACHILLES THERAPEUTICS

ARCTURUS THERAPEUTICS